Else Kröner Fresenius Prize for Medical Research 2025

In honour of the outstanding lifetime achievements of Else Kröner, the founder of the Else Kröner-Fresenius-Stiftung, the foundation has established this major biennial research prize to be awarded in a specified field of biomedical science. The field chosen for 2025 is RNA-based therapies.

The prize amounts to EUR 2.5 million, of which EUR 500,000 shall be awarded personally to the recipient and EUR 2.0 million dedicated to the award-winner’s future research.

Cutting-edge research on RNA-based therapies: Else Kröner-Fresenius-Stiftung announces Prize for Medical Research 2025

Bad Homburg v.d. Höhe, June 5, 2024 – Today the foundation Else Kröner-Fresenius-Stiftung (EKFS) announced its call for proposals for the Else Kröner Fresenius Prize for Medical Research 2025. Endowed with 2.5 million euros, the prize will be awarded next year for outstanding achievements in the field of RNA-based therapies.

Nachgefragt: Was macht eigentlich Prof. Dr. Simon Lebek, Else Kröner Memorialstipendiat aus dem Jahr 2023?

Nach seinem Medizinstudium erfüllte Prof. Dr. Simon Lebek 2021 die Voraussetzungen zur Habilitation in Experimenteller Innerer Medizin an der Universität Regensburg. Im selben Jahr schloss er sich der Arbeitsgruppe von Prof. Dr. Eric Olson am UT Southwestern Medical Center in Dallas, USA, an. Sein Auslandsaufenthalt wurde mit dem Walter Benjamin-Stipendium der Deutschen Forschungsgemeinschaft gefördert. Während seines Postdocs im „Olson Lab“ lernte er neben vielen molekularbiologischen Methoden vor allem das CRISPR-Cas9 Gene Editing – auch als Gen-Schere bekannt – kennen.

Extracorporeal Life Support in Infarct-Related Cardiogenic Shock (ECLS-SHOCK)

Cardiogenic shock is caused by a pump failure of the heart and in most cases caused by a heart attack. Currently, still 40-50% of these patients die. For more than ten years, cardiogenic shock has been treated with venoarterial extracorporeal membrane oxygenation, which is called VA-ECMO or ECLS, to support the failing heart. In the large ECLS-SHOCK trial, in which a total of 420 patients with cardiogenic shock after myocardial infarction at 44 centers in Germany and Slovenia participated, VA-ECMO therapy in the intensive care unit was compared versus no VA-ECMO in the intensive care unit.

Subscribe to Scientific Funding